Boehringer Ingelheim reaches more patients in 2024 and prepares new medicine launches
Boehringer Ingelheim today announced a continued rise in the number of patients it reached, 66 million in 2024, up 8.0% from the previous year. Development of its current product pipeline is well on track, as the company prepares multiple new product launches, starting in 2025. Research & Development (R&D) investments rose to EUR 6.2 billion, or 23.2% of group net sales. Group net sales rose by 6.1%* to EUR 26.8 billion.
'As our current pipeline continues to mature and more products come closer to a potential market introduction, we have entered a pivotal phase of high investments, to bring these new innovations to patients,' said Hubertus von Baumbach, Chairman of the Board of Managing Directors. 'It is important that we use every opportunity to bring these new treatments to patients as fast as possible – this is our number one priority.' Strong Growth in IMETA
In India, Middle East, Turkey, and Africa (IMETA) region, the company recorded net sales of 855 million EUR (2023: 732 million EUR), a 17% increase compared to the previous year.
Derek O'Leary, Regional Managing Director at Boehringer Ingelheim India, Middle East, Turkey and Africa (IMETA) said: 'Our strong performance in 2024 underscores our commitment to addressing unmet medical needs in both human and animal health. We will continue to work towards expanding access to innovative treatments for people and strengthen our efforts to safeguard animal health and well-being, impacting a greater number of lives. In partnerhip with our stakeholders, we are eager to build on this momentum in 2025 through further science-backed innovations tailored to the needs of both patients and animals.' Human Pharma: investing in existing products and new launches
Human Pharma sales rose by 7.0%* to EUR 21.9 billion, led by the treatment of chronic kidney diseases, type 2 diabetes and heart failure, rose 14.6%* to EUR 8.4 billion. Treatments used for idiopathic pulmonary fibrosis and certain fibrosing interstitial lung diseases, grew 8.9%* to EUR 3.8 billion.
The Human Pharma pipeline includes over ten new Phase II and III trials over the next 12 to 18 months, which will potentially result in a range of significant launches in the next five years. Human Pharma R&D spending rose to EUR 5.7 billion, or 27.6% of the business unit's net sales.
'If we look at the past five years, Boehringer Ingelheim has invested approximately EUR 25 billion in R&D,' said Frank Hübler, Member of the Board of Managing Directors with responsibility for Finance. 'With the innovations currently in our pipeline we will further increase investments in R&D in the years to come.'
After positive data from pivotal studies, the company is preparing multiple new product launches to advance care for patients with Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis as well as the first orally administered, targeted therapy for previously treated HER2-mutated lung cancer patients.
Both treatments have been submitted to regulatory authorities globally and first launches in the US are anticipated in the second half of this year, pending approval. Animal Health: rapid response against transboundary animal diseases
Animal Health sales rose 1.9%* to EUR 4.7 billion in 2024, mainly driven by Pet Parasiticides and Therapeutics, Poultry and Ruminant. The parasiticides continued to strengthen its position as the top-selling brand in the industry, growing 14.0%* to EUR 1.4 billion.
Last year, Boehringer Ingelheim supported livestock producers and governments by quickly providing vaccines and technical assistance for outbreaks of transboundary animal diseases (TADs), such as avian influenza, bluetongue virus and foot-and-mouth disease. These diseases pose a significant risk to animal health, impede global trade, and constrain food supply. Sustainable Development
Boehringer Ingelheim is on track in its target to become carbon neutral in its company operations by 2030. It increased global renewable electricity purchases to around 75% in 2024, primarily due to transitioning to renewable solutions at various sites, including Japan and China. A new biomass power plant was also commissioned at its Ingelheim site in Germany to boost on-site renewable energy generation to 95% of its energy needs.
As part of its global effort to stop rabies, the company provided 46 million rabies vaccine doses and supported vaccination campaigns in endemic countries. The 'Angels' initiative, which aims to optimize the quality of treatment in existing stroke centers, added over 1,000 organizations to the network. It is the largest stroke community in the world, now encompassing 237,000 healthcare professionals from more than 9,000 hospitals in 158 countries and has helped 19 million stroke patients to date. Outlook
The general trends and developments of the past year are expected to continue to impact 2025. The company expects a continued rise in the number of patients reached, and a slight year-on-year increase in net sales, adjusted for currency and extraordinary effects.
* sales growth numbers are adjusted for currency effects
**one-sided p-value from a z-test of the null hypothesis ORR ?30%
Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at Boehringer Ingelheim – Life Forward | Boehringer Ingelheim.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
6 days ago
- Zawya
DoH and Boehringer Ingelheim Ink strategic partnership to advance life science innovation across the Emirate
Abu Dhabi, United Arab Emirates: The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, signed a Memorandum of Understanding (MoU) with Boehringer Ingelheim, one of the world's leading research-driven pharmaceutical companies. This strategic partnership aims to advance scientific research and innovation, foster groundbreaking research and development and cultivate an environment of scientific excellence, further cementing the Emirate as the MENA region's premier hub for healthcare, life sciences and innovation. In the presence of H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi and Ousama Alhaj, General Manager and Head of Human Pharma, Near East and UAE at BI, the agreement was signed during BIO International Convention in Boston at the Abu Dhabi Pavilion by Dr. Asma Al Mannaei, the Executive Director of the Health Life Sciences Sector at the DoH and Ghaleb Al Ahdab, Head of Public and Government Affairs, Near East and UAE at BI. Through this strategic partnership, the two parties seek to strengthen the Emirate's research ecosystem by facilitating access to and harnessing the capabilities of Boehringer Ingelheim'sOpnME platform. Researchers, scientists and innovators across Abu Dhabi will be able to leverage the platform's cutting-edge data and resources to address critical biological challenges and accelerate scientific discovery. Through four flagship programmes, Molecule to Order (M2O), Molecule for Collaboration (M4C), opn2EXPERTS (o2e) and opnTALENTS (o25), the platform empowers the research community with access to advanced compounds, collaborative opportunities, expert networks and support for emerging talent. OpnME connects visionary researchers to champion transformative, research-driven medical innovation for generations to come. In line with Abu Dhabi's vision to shape the future of healthcare, this partnership between DoH and BI enhances knowledge exchange and invests in local talent. It offers scientists a purpose-driven, globally connected environment to lead impactful research, further reinforcing the Emirate's commitment to transforming the regional healthcare ecosystem through science and technology. Dr. Asma Ibrahim Al Mannaei, the Executive Director of the Health Life Sciences Sector at DoH, said: 'Our partnership with Boehringer Ingelheim reflects our commitment to pioneering innovation and scientific research as parts of our efforts to advance health outcomes and improve the quality of life for communities around the world. We're empowering Abu Dhabi researchers with the opnMe platform, an open portal offering top-tier pharmaceutical compounds, fostering collaboration and safeguarding researchers' rights to their findings. This is about transforming our emirate into a global life sciences hub, speeding up breakthroughs, and building a healthier, resilient future for all.' Ousama Alhaj, General Manager and Head of Human Pharma for Near East and UAE at Boehringer Ingelheim, said: 'At Boehringer Ingelheim, we are proud to partner with the Department of Health – Abu Dhabi (DoH) to empower the scientific community through our OpnMe platform. This collaboration reflects our shared commitment to advancing research and innovation in the region, fostering a culture of discovery, and ultimately improving patient outcomes. By providing access to our scientific resources, including advanced compounds, collaborative research opportunities, and expert networks, we aim to inspire new ideas and support the next generation of researchers in Abu Dhabi.' Led by DoH, a high-level delegation has embarked on a strategic mission to the United States from June 14 to 21, delegation will conduct over 20 strategic meetings and visits with public and private sector leaders across the U.S., aimed at knowledge exchange, investment opportunities and the signing of new agreements that accelerate the adoption of advanced health solutions. Representing Abu Dhabi's innovation ecosystem, the delegation includes key stakeholders such as the Abu Dhabi Investment Office, Mubadala BIO, M42, Masdar City, KEZAD, PureHealth, and Etihad Cargo, New York University Abu Dhabi (NYUAD), Khalifa University, startAD and Mohamed bin Zayed University of Artificial Intelligence (MBZUAI). About the Department of Health – Abu Dhabi (DoH): The Department of Health – Abu Dhabi is the regulative body of the healthcare sector in the Emirate of Abu Dhabi. Committed to ensuring excellence in healthcare, DoH monitors the health status of the population while shaping the regulatory framework for the health system. This includes inspecting against regulations, enforcing standards and encouraging the adoption of world-class best practices and performance targets by all healthcare providers in the Emirate. Abu Dhabi remains dedicated to shaping the future of healthcare by establishing an intelligent and sustainable ecosystem that prioritises health, longevity and quality of life for all community members. Leveraging state-of-the-art infrastructure and cutting-edge capabilities, DoH continues to develop and implement initiatives and programmes in line with its strategic focus areas, Healthy Population, Best-in-Class Care and Resilience and Innovation. These efforts reflect DoH's unwavering commitment to predicting, preventing and personalising healthcare for every individual.
Al Etihad
6 days ago
- Al Etihad
Department of Health - Abu Dhabi, Boehringer Ingelheim ink strategic partnership
17 June 2025 13:56 ABU DHABI (WAM) The Department of Health - Abu Dhabi (DoH) signed a Memorandum of Understanding with Boehringer Ingelheim, one of the world's leading research-driven pharmaceutical strategic partnership aims to advance scientific research and innovation, foster groundbreaking research and development, and cultivate an environment of scientific excellence, further cementing the emirate as the MENA region's premier hub for healthcare, life sciences, and the presence of Dr. Noura Khamis Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi and Ousama Alhaj, General Manager and Head of Human Pharma, Near East and UAE at BI, the agreement was signed during BIO International Convention in Boston at the Abu Dhabi Pavilion by Dr. Asma Al Mannaei, the Executive Director of the Health Life Sciences Sector at the DoH and Ghaleb Al Ahdab, Head of Public and Government Affairs, Near East and UAE at this strategic partnership, the two parties seek to strengthen the Emirate's research ecosystem by facilitating access to and harnessing the capabilities of Boehringer Ingelheim's OpnME scientists, and innovators across Abu Dhabi will be able to leverage the platform's cutting-edge data and resources to address critical biological challenges and accelerate scientific four flagship programmes, Molecule to Order (M2O), Molecule for Collaboration (M4C), opn2EXPERTS (o2e) and opnTALENTS (o25), the platform empowers the research community with access to advanced compounds, collaborative opportunities, expert networks, and support for emerging connects visionary researchers to champion transformative, research-driven medical innovation for generations to Mannaei said, 'Our partnership with Boehringer Ingelheim reflects our commitment to pioneering innovation and scientific research as part of our efforts to advance health outcomes and improve the quality of life for communities around the empowering Abu Dhabi researchers with the opnMe platform, an open portal offering top-tier pharmaceutical compounds, fostering collaboration and safeguarding researchers' rights to their findings. This is about transforming our emirate into a global life sciences hub, speeding up breakthroughs, and building a healthier, resilient future for all.' Alhaj said, 'At Boehringer Ingelheim, we are proud to partner with the Department of Health – Abu Dhabi (DoH) to empower the scientific community through our OpnMe platform. This collaboration supports research, innovation, and the next generation of researchers in the region.'
Web Release
11-06-2025
- Web Release
HIMA Group continues growth path, strengthening its position as key solutions provider
HIMA Group, a leading provider of safety-related automation solutions, has continued its significant growth path in the fiscal year 2024. Revenue increased to EUR 186 million, driven largely by international expansion and an increasing focus on digital solutions. Following an already very successful fiscal year 2023, the HIMA Group continued its growth momentum in 2024. Revenue rose by 23 percent, from EUR 151 million in 2023 to EUR 186 million in 2024. Organic growth was 12 percent in 2024. Jörg de la Motte, CEO of HIMA Group, said, 'With the acquisition of Sella Controls and Origo Solutions in 2023 and 2024, we have brought new expertise into the company and strengthened our market position as a key solutions provider. In addition, we have further expanded our operations outside Europe to support demanding customer projects locally.' In Europe, 24 percent of sales were generated from Germany, Austria and Switzerland, 19 percent from other EU countries, 11 percent from the United Kingdom, and 9 percent from Norway. The Asia-Pacific region contributed 19 percent to sales, followed by the Middle East and India with 12 percent and the Americas with 6 percent. Dr. Michael Löbig, CFO of HIMA Group, said, 'The encouraging sales performance is a clear signal of the viability of our business model. We expect further sales growth in the current year, although the market environment remains challenging, particularly in Germany.' Railway sector witnessed strong growth In 2024, HIMA recorded substantial growth, particularly in the railway sector, with one of the reasons being new customer projects supported by Sella Controls. The railway industry now accounts for 17 percent of sales. An expanded product and solution portfolio was presented for the first time at InnoTrans 2024. It was very well received by trade visitors, particularly because of its high flexibility, easy integration, cost efficiency, and ability to promote the digital transformation of railway transport. International expansion continues Following the opening of a new subsidiary in Saudi Arabia in 2023, another was established in India in November 2024. In addition, new sales offices and service centers were opened in several countries. In China, for example, a new service center commenced operations in Zhanjiang to better serve customers in the southeastern part of the country. In addition, a subsidiary was opened in Colombia, and a branch is planned in Peru. Further expansion in these growth markets is planned to support large and demanding customer projects locally. In regions where the HIMA Group does not have a direct presence, the partner program has been further expanded. 'With these investments in high-growth regions, we are further expanding our customer proximity and strengthening our international position,' added Jörg de la Motte. Investments in digitalization and artificial intelligence (AI) The portfolio has been expanded to include new digital solutions such as cockpits for controlling safety lifecycle management, SCADA+, and safeHMI. The safeHMI, developed in partnership with DEUTA-Werke, replaces classic, hard-wired visualization solutions with secure, flexible control panels. The long-standing cooperation with security specialist genua has also been further intensified in order to strengthen the resilience of automation systems against cyber threats. Jörg de la Motte said, 'Our strategy with a clear focus on digitalization under the motto #safetygoesdigital is paying off. With our digital cockpits for controlling safety lifecycle management, safeHMI, and SCADA+, we offer our customers real added value.' Continuing education is also embracing digitization. With the 'Digital HIMA Academy', the company is digitizing all training processes and offering employees and customers a digital learning platform. HIMA Group is increasingly focusing on AI-based innovations and has expanded its own innovation lab, 'himalaya', in Mannheim to accommodate this. Solutions developed here that are already in pilot use include AI-supported remote diagnosis, which detects anomalies in safety control systems at an early stage and enables proactive maintenance. The company's internal chatbot, 'Ask Paula', which specializes in functional safety, will be introduced in June 2025. Dr. Michael Löbig said, 'AI has great potential for HIMA Group, both internally and externally. Our innovation lab, 'himalaya', is the right place to quickly identify and tap into applications and potential.' Sustainability as a priority 'At HIMA Group, sustainability is a central component of our corporate philosophy and serves to secure the future of our company,' explains Steffen Philipp, Managing Partner of HIMA Group. This is particularly evident in the responsible use of resources and the protection of people and the environment. To operate successfully and responsibly in the long term, HIMA pursues economic, ecological, and social goals. These include participation in sustainability initiatives, the establishment of a global CSRD team, sustainable location and trade fair concepts, as well as ideas competitions and awards for particularly successfully implemented projects. 'For every customer feedback, HIMA makes a contribution to tree planting and thus makes an active contribution to environmental protection,' adds Dr. Michael Löbig.
